Thomas Repas, DO
Pulmonary Disease · Gillette, WYNPI 1134180516
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Amgen at 33.5% of the total. Reporting peaked in 2019 at $7,785 and has fallen 90.2% since, to $762 in 2025.
Across 131 payments — averaging $169.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Regeneron Healthcare Solutions, Inc.$6K
- Merck$4K
- Novo Nordisk$2K
- Kaneka Medical America LLC$2K
- Corcept Therapeutics$473
- plus $1K from 18 others
What the payments were for
- Consulting fees$6,56430%
- Speaking & faculty fees$9,46543%
- Travel & lodging$3,38515%
- Food & beverage$2,75412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $7,430 |
| Regeneron Healthcare Solutions, Inc. | 17 | $5,525 |
| Merck | 17 | $3,600 |
| Novo Nordisk | 15 | $2,266 |
| Kaneka Medical America LLC | 2 | $1,799 |
| Corcept Therapeutics | 12 | $473 |
| Lilly USA, LLC | 9 | $208 |
| AstraZeneca(2 entities) | 9 | $193 |
| Sanofi-aventis U.S. LLC | 9 | $134 |
| Medtronic | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 1 | $85 |
| Novartis | 3 | $53 |
| Abbott | 2 | $41 |
| Philips North America LLC | 2 | $41 |
| Recordati_rare_diseases_inc. | 2 | $37 |
| UCB, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $28 |
| Astellas Pharma US Inc | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Mimedx Group, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pulmonary disease providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvkeezaEvinacumab-Dgnb | 12 | $903,476 |
| JardianceEmpagliflozin | 44 | $54,353 |
| OzempicSemaglutide | 27 | $41,381 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $39,209 |
| TrulicityDulaglutide | 34 | $34,747 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $23,875 |
| Repatha SureclickEvolocumab | 36 | $20,888 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $14,685 |
| MounjaroTirzepatide | 11 | $13,897 |
| SynthroidLevothyroxine Sodium | 129 | $13,458 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $8,951 |
| HumalogInsulin Lispro | 13 | $4,205 |
| Desmopressin Acetate | 12 | $2,998 |
| Hydrocortisone | 44 | $2,991 |
| Levothyroxine Sodium | 324 | $2,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Evkeeza | $5,525 | $903,47612 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $208 | $52,84958 claims |
| Novo NordiskOzempic | $2,266 | $41,38127 claims |
| AbbVieSynthroid | $13 | $13,458129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pulmonary disease providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other pulmonary disease in Gillette
- Rage GeringerCheyenne$7K
- David ShraderAfton$2K
- Jack MaloneCasper$753
- Muhammad HussienoCasper$753
- Stephen MaininiCody$536
- Steven ReebCheyenne$111
- Jonathan BoltaxJackson$90
- H Kenneth FisherCasper$41
- Manish AggarwalCheyenne$32
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.